These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Vaccination models and optimal control strategies to dengue. Rodrigues HS; Monteiro MT; Torres DF Math Biosci; 2014 Jan; 247():1-12. PubMed ID: 24513243 [TBL] [Abstract][Full Text] [Related]
23. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Thomas SJ Hum Vaccin Immunother; 2013 Jul; 9(7):1587-90. PubMed ID: 23466948 [TBL] [Abstract][Full Text] [Related]
24. Unique challenges faced by the clinical evaluation of dengue vaccines. Edelman R Expert Rev Vaccines; 2011 Feb; 10(2):133-6. PubMed ID: 21332260 [No Abstract] [Full Text] [Related]
25. T cell immunity to dengue virus and implications for vaccine design. Rivino L Expert Rev Vaccines; 2016; 15(4):443-53. PubMed ID: 26560171 [TBL] [Abstract][Full Text] [Related]
26. Vaccination Against Dengue: Challenges and Current Developments. Guy B; Lang J; Saville M; Jackson N Annu Rev Med; 2016; 67():387-404. PubMed ID: 26515983 [TBL] [Abstract][Full Text] [Related]
27. The Interplay of Dengue Virus Morphological Diversity and Human Antibodies. Lok SM Trends Microbiol; 2016 Apr; 24(4):284-293. PubMed ID: 26747581 [TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of a Live Dengue Vaccine (TAK-003). de Silva A; White L J Infect Dis; 2022 Dec; 227(1):163-164. PubMed ID: 36285800 [No Abstract] [Full Text] [Related]
29. Vaccines licensed and in clinical trials for the prevention of dengue. Torresi J; Ebert G; Pellegrini M Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864 [TBL] [Abstract][Full Text] [Related]
30. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens. Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114 [TBL] [Abstract][Full Text] [Related]
31. DENGUE VACCINES. Thisyakorn U; Thisyakorn C Southeast Asian J Trop Med Public Health; 2015; 46 Suppl 1():138-45. PubMed ID: 26506740 [TBL] [Abstract][Full Text] [Related]
32. Experimental in vitro and in vivo systems for studying the innate immune response during dengue virus infections. Kitab B; Kohara M; Tsukiyama-Kohara K Arch Virol; 2018 Jul; 163(7):1717-1726. PubMed ID: 29520688 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response. Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832 [TBL] [Abstract][Full Text] [Related]
34. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647 [TBL] [Abstract][Full Text] [Related]
38. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design. Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764 [TBL] [Abstract][Full Text] [Related]
39. Analyzing the development of vaccines for flavivirus-endemic scenarios: the case of Dengue and Dengue vaccine in Peru. Ruiz-Alejos A; Navarro-Huaman L; Segura ER J Infect Dis; 2013 Oct; 208(7):1183. PubMed ID: 23852123 [No Abstract] [Full Text] [Related]